Skip to content

Cumberland Low Back Pain Trial

The effect of motor control exercise versus placebo in patients with chronic low back pain

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12605000262606
Enrollment
154
Registered
2005-09-02
Start date
2005-10-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Patients will be randomly assigned to one of 2 groups. Both groups will attend 12 x 1/2 hour sessions of treatment over an 8 week period. Group 1 will receive a motor control exercise program designed to restore control of the trunk muscles.

Sponsors

University of Sydney
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

(i)Non-specific low back pain +/- leg pain of at least 3 months duration (ii)Currently seeking care for low back pain (iii) English speaker (iv)Clinical assessment indicates that the subject is suitable for motor control exercise.

Exclusion criteria

(i)Suspected or confirmed serious spinal pathology (fracture, metastatic, inflammatory or infective diseases of the spine, cauda equina syndrome/widespread neurological disorder).(ii)Suspected or confirmed pregnancy(iii)Are unable to speak English(iv)Nerve root compromise (2 of strength, reflex or sensation affected for same nerve root)(v)Spinal surgery in the past 12 months.(vi)Scheduled for major surgery during treatment or follow-up period (vii)Any of the contraindications to exercise listed on page 42 of the ACSM guidelines (ACSM's Guidelines for Exercise Testing and Prescription, 1995).(viii)Any contraindication to pulsed ultrasound or pulsed shortwave.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026